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Conclusions: No significant relationship between the mean 
dose to the salivary apparatus and subjective xerostomia was 
observed. However, this study did show that despite 
undergoing parotid sparing IMRT, a large number of patients 
still display a high degree of symptomology for years after 
treatment, but these symptoms do not appear to have a 
deleterious effect on quality of life in survivors. Patients’ 
perceptions are subject to change after a diagnosis of H&N 
cancer. This study strongly suggests that a psychological 
adjustment of patients to their symptoms and a redefinition 
of their expectations is possible.  
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Recently the first replicated genetic associations and GWAS 
for adverse reactions to radiotherapy have been reported. 
These will help to build predictive statistical models for 
optimising radiotherapy delivery or interventions to alleviate 
the side effects. It is now important to validate known 
predictors of adverse reactions and develop the statistical 
models to become clinically useful. The REQUITE project is a 
European Union funded FP7 project that aims to do this. 
REQUITE’s objectives: 
1. Perform a multi-centre, cohort study collecting: blood 
samples, epidemiology and treatment data, longitudinal side-
effect and QOL data (before and after treatment, years 1 & 
2). 
2. Produce a centralised biobank of DNA from 5,300 patients 
with centralised data management. 
3. Validate published biomarkers of radiosensitivity. 
4. Validate clinical predictors of radiotherapy toxicity in 
breast, prostate and lung cancer and incorporate biomarker 
data. 
5. Design interventional trials to reduce long-term side-
effects. 
6. Provide a resource for dissemination and exploitation to 
the radiotherapy community. 
REQUITE is funded for 60 months from October 2013 and 
organised into seven work packages. WP1 is responsible for 
overall management and scientific oversight run by 
Manchester. The central activity of the project is a multi-
centre, observational study organised through WP2, led by 
DKFZ. Enrolment began in April 2014 and will proceed for 2 
years in nine clinical centres, with 2 years follow-up. Current 
recruitment has exceeded 500 patients. The primary 
endpoints are change in breast appearance; rectal bleeding 
(prostate); pneumonitis (lung). The integrated database has 
been designed at Leicester. 
Blood samples are being collected before radiotherapy. 
Tracking, biobanking and DNA preparation is handled in WP3 
at CIGMR in Manchester. Validation of biomarkers (genetic 
markers and apoptosis assays) as predictive factors is being 
carried out in WP4 led by Leicester. Preliminary work has 
reduced inter-laboratory variation in the FACS-based 
apoptosis assay between Leicester, Mannheim and 
Montpellier. The assay is now being carried out on all samples 
collected through the three centres. The data will establish 
whether the assay can be used as a standard test to predict 
radiotherapy toxicity. 
In WP5 Gent is leading in validating published models in 
existing cohorts, leading to replicated models that can be 
validated using the REQUITE cohorts. In WP6 Leuven will use 
the predictive models to design clinical interventional trials 
and produce protocols that seek to lower radiotherapy side-
effects in those individuals at high risk of developing them 
without affecting tumour control. Dissemination and 
Outreach is being co-ordinated through WP7 led by MAASTRO. 
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Biomarkers of normal tissue toxicity are used in determining 
predictive models of toxicity and may help understanding of 
the biology of radiation response in normal tissue. 
Whilst clinical assessment of toxicity has been evaluated 
quantitatively, this often encompasses complex clinical 
endpoints, incorporating different pathological entities. 
Other quantitative assessments of normal tissue effects 
which may more directly reflect underlying pathological 
alterations in tissue include imaging at the anatomical or 
functional level, and measurement of cell or molecular 
alterations in blood or tissue. These approaches may improve 
descriptive radiobiology or the characterization of late 
normal tissue effects. 
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Elevation of tissue response markers after radiotherapy may 
occur in patients classified using clinical scoring as ‘non 
responders’ suggesting that the difference in cell and 
molecular phenotype between ‘responders’ and ‘non 
responders’ is not understood and that there may in fact be a 
spectrum of subclinical changes at the tissue level across the 
two groups. 
Identification of biomarkers used as simple biological 
endpoints of normal tissue toxicity may therefore be useful in 
the following settings: 
1) A tool for scoring or characterisation of established late 
normal tissue effects which could be used in conjunction with 
clinical score. 
2) To assess response to therapy. 
3) To improve classification between ‘responders’ and ‘non 
responders’ in terms of radiotherapy toxicity. 
4) As response markers, involved mechanistically in the 
radiation response, to improve understanding underlying 
molecular pathology or phenotype. 
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With advances in multi-modality therapy, childhood cancer 
cure rates approach 80%. However, both radiotherapy and 
chemotherapy may cause debilitating or even fatal “late 
effects” that are critical to document, mitigate, or prevent. 
QUANTEC provided a comprehensive overview of dose-
volume-response relationships for adverse effects of radiation 
therapy in adults. Special attention for data on children 
treated with radiation therapy is needed, because of the 
intrinsic role of growth and development both during 
radiation exposure as well as in the attained life span, the 
much longer life-expectancy for children, and the less 
prominent role of co-morbidities.  
PENTEC is a research collaboration aiming to critically 
analyze radiation dose-volume effects on normal tissue 
tolerances and second cancer risk as a function of 
age/development in pediatric cancer patients in order to: (a) 
inform treatment planning; (b) improve outcomes for 
survivors; (c) describe relevant physics issues specific to 
pediatric radiotherapy; and (d) propose dose volume outcome 
reporting standards to improve the knowledge base to inform 
future treatment guidelines. Late effects occurring decades 
after therapy, such as second malignancies and other health 
problems, are a special concern for pediatric cancer 
survivors. 
The impact of other critical contributors to normal tissue 
damage, including chemotherapy, surgery, stem cell 
transplantation and underlying genetic predispositions will 
also be considered. The Consortium Steering Committee 
(Chair: Prof L.S. Constine) has representation from many 
different disciplines, including radiation oncology, pediatric 
oncology, medical physics, radiology, radiobiology, 
biomathematics/biostatistical modelling, epidemiology and 
evidence-based medicine.  We have developed protocols on 
several topics including guidance for systematic literature 
searches, data extraction. We are currently identifying 
literature and developing data analysis guidance.  
In this presentation we focus on an outline of the content, 
methods and challenges, and  on the current status of the 
literature selection process.  
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Purpose/Objective: Classically radiotherapy for soft tissue 
sarcoma in extremities had to include a strip of normal tissue 
for preventing lymphedema. Lterature shows that dermal 
lymphatics, whose obstruction causes lymphedema, lay at a 
1.5-2mm form the surface. This location implies that energy 
deposition in the superficial area is basic for explaining this 
side effect. 
Cobalt units did indeed irradiate this superficial layer, 
(maximum 0.5.cm) thus making necessary leaving a non –
irradiated strip. The use of higher energies such as 6 MV and 
higher (maximum at least at 1.5 cm,) avoids significant dose 
in the first millimeters, so the superficial layers are not 
irradiated, thus a normal strip would be unnecessary 
Materials and Methods: Treatment planning for extremities 
soft tissue sarcoma was performed in 10 patients, with 
different beam energies. The dose in build up region or 
superficial, was quantified, for every situation and different 
beam parameters: a comparison was made between high and 
low energy, and also to theoretical Cobalt distribution 
Results: 6 and 15 MV beams spared tissue in buid up radiation 
in the first millimeters. Volumetric studies showed that in a 
large treatment area, this implied that there was also a large 
supeficial non irradiated volume; this effect was greater for 
higher energies, and practically nonexistent for Cobalt 
Conclusions: The need for leaving a strip of tissue without 
irradiation comes from a time when beam energy did not 
spare the first milimeters. Also in some situations the strip 
would avoid a correct irradiation of the target volume. As 
superficial layers are spared with current beam energies, the 
strip would be unnecessary. So there would be no restrictions 
for treatment planning. The higher the energy, the bigger the 
effect, this might imply that the beam energy in sarcoma 
should be as high as possible preserving the radiation of 
CTV/PTV. 
